Clinical Trial Detail

NCT ID NCT03392246
Title A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

lung non-small cell carcinoma

Therapies

Osimertinib + Selumetinib

Age Groups: adult senior

No variant requirements are available.